Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.

ABSTRACT:

Background

Retinopathy of prematurity is a leading cause of childhood blindness worldwide. Peripheral retinal ablation with conventional (confluent) laser therapy is destructive, causes complications, and does not prevent all vision loss, especially in cases of retinopathy of prematurity affecting zone I of the eye. Case series in which patients were treated with vascular endothelial growth factor inhibitors suggest that these agents may be useful in treating retinopathy of prematurity.

Methods

We conducted a prospective, controlled, randomized, stratified, multicenter trial to assess intravitreal bevacizumab monotherapy for zone I or zone II posterior stage 3+ (i.e., stage 3 with plus disease) retinopathy of prematurity. Infants were randomly assigned to receive intravitrea

SUBMITTER: Mintz-Hittner HA 

PROVIDER: S-EPMC3119530 | biostudies-literature | 2011 Feb

REPOSITORIES: biostudies-literature